
RealRate

PHARMACEUTICAL 2021

EYENOVIA INC. Rank 275 of 409







PHARMACEUTICAL 2021

EYENOVIA INC. Rank 275 of 409



The relative strengths and weaknesses of EYENOVIA INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of EYENOVIA INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 48% points. The greatest weakness of EYENOVIA INC. is the variable Net Income, reducing the Economic Capital Ratio by 84% points.

The company's Economic Capital Ratio, given in the ranking table, is -242%, being 113% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	33,391
Cost of Goods Sold	800
Intangible Assets	0
Liabilities, Current	18,198
Liabilities, Non-Current	0
Other Assets	119
Other Compr. Net Income	0
Other Expenses	17
Other Liabilities	404
Other Net Income	36
Property and Equipment	396
Research and Development	13,264
Revenues	2,000
Selling, General and Administrative Expense	7,725

Output Variable	Value in 1000 USD
Assets	33,907
Liabilities	18,603
Expenses	21,806
Stockholders Equity	15,304
Net Income	-19,770
Comprehensive Net Income	-19,770
Economic Capital Ratio	-242%